Clinical data
Routes of
By mouth, IV
ATC code None
Legal status
Legal status
  • Development terminated
Pharmacokinetic data
Metabolism Mainly unchanged, ~15% N-demethylation[1]
Excretion Urine, faeces
Synonyms PRT-060128
CAS Number 936500-94-6
PubChem (CID) 16066663
ChemSpider 17226246
UNII 915Y8E749J YesY
KEGG D09607
Chemical and physical data
Formula C20H15ClFN5O5S2
Molar mass 523.945 g/mol
3D model (Jmol) Interactive image

Elinogrel (INN,[2] USAN) was an experimental antiplatelet drug acting as a P2Y12 inhibitor. Similarly to ticagrelor and in contrast to clopidogrel, elinogrel was a reversible inhibitor that acted fast and short (for about 12 hours), and it was not a prodrug but pharmacologically active itself. The substance was used in form of its potassium salt, intravenously for acute treatment and orally for long-term treatment.[3] Development was terminated in 2012.


The substance was originally developed by Portola Pharmaceuticals, with Phase II clinical trials conducted around 20082011.[4] In February 2009, Novartis bought worldwide rights to develop it further, intending to conduct Phase III studies and commercialise the drug.[5] The development of the drug was terminated in January 2012 by Novartis.[6]


  1. Siller-Matula, J. M.; Krumphuber, J.; Jilma, B. (2010). "Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases". British Journal of Pharmacology. 159 (3): 502–517. doi:10.1111/j.1476-5381.2009.00555.x. PMC 2828016Freely accessible. PMID 20050853.
  2. "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 63" (PDF). World Health Organization. pp. 50–1. Retrieved 1 December 2016.
  3. Gurbel, P.A.; Kereiakes, D.; Tantry, U.S. (2010). "Elinogrel potassium". Drugs Fut. 35 (11): 885.
  4. Michelson, A. D. (2011). "Advances in Antiplatelet Therapy". Hematology. 2011: 62–69. doi:10.1182/asheducation-2011.1.62. PMID 22160013.
  5. Insciences: Novartis gains worldwide rights to elinogrel, a Phase II anti-clotting compound with potential to reduce risk of heart attack
  6. BioPortfolio: Novartis drops elinogrel outright
This article is issued from Wikipedia - version of the 12/1/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.